Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome

OBJECTIVE: Rituximab is an effective treatment for children with steroid dependent or frequently relapsing nephrotic syndrome. The optimum dosing schedule for rituximab has not been established. We hypothesized that a single low dose of 375 mg/m(2) would have comparable outcomes to higher doses in r...

Descripción completa

Detalles Bibliográficos
Autores principales: Maxted, Andrew P., Dalrymple, Rebecca A., Chisholm, Denise, McColl, John, Tse, Yincent, Christian, Martin T., Reynolds, Ben C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424916/
https://www.ncbi.nlm.nih.gov/pubmed/30564878
http://dx.doi.org/10.1007/s00467-018-4172-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424916/
https://www.ncbi.nlm.nih.gov/pubmed/30564878
http://dx.doi.org/10.1007/s00467-018-4172-3

Ejemplares similares